Biomarkers /
CDK5
Back to Biomarkers List
Associated Diseases
Overview
CDK5 is altered in 0.67% of all cancers with lung adenocarcinoma, colon adenocarcinoma, high grade ovarian serous adenocarcinoma, bladder urothelial carcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in CDK5 are CDK5 Mutation (0.55%), CDK5 Amplification (0.08%), CDK5 M230V (0.04%), CDK5 R24W (0.04%), and CDK5 D207N (0.02%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.